Nuformix plc (LON:NFX – Get Free Report) rose 10.6% on Tuesday . The company traded as high as GBX 0.09 ($0.00) and last traded at GBX 0.09 ($0.00). Approximately 14,352,294 shares traded hands during trading, a decline of 79% from the average daily volume of 69,985,758 shares. The stock had previously closed at GBX 0.09 ($0.00).
Nuformix Trading Up 10.6 %
The business has a 50-day moving average price of GBX 0.07 and a 200-day moving average price of GBX 0.08. The firm has a market cap of £1.16 million, a P/E ratio of -2.86 and a beta of 1.22.
Nuformix (LON:NFX – Get Free Report) last issued its quarterly earnings data on Wednesday, January 29th. The company reported GBX (0.46) (($0.01)) EPS for the quarter.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
See Also
- Five stocks we like better than Nuformix
- Investing in Commodities: What Are They? How to Invest in Them
- Confluent: How Data Streaming May Transform AI
- Value Investing: Is it a Good Strategy in 2022? (Hint: Always)
- The Behemoth BlackRock’s Next Trillion Comes From Private Assets
- Business Services Stocks Investing
- Rivian’s Rough Patch: Is the Dip a Doorway to Long-Term Gains?
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
